UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro

Oncotarget, 2017-09, Vol.8 (43), p.74688-74702

2017

Volltextzugriff (PDF)

An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin

British journal of haematology, 2014-06, Vol.165 (6), p.870-882

2014

Volltextzugriff (PDF)

Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody

Cancer Immunology, Immunotherapy, 2022-02, Vol.71 (2), p.473-489

2022

Volltextzugriff (PDF)

Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint

Molecular cancer therapeutics, 2018-08, Vol.17 (8), p.1727-1738

2018

Volltextzugriff (PDF)

Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G 1 -S Checkpoint

Molecular cancer therapeutics, 2018-08, Vol.17 (8), p.1727

2018

Volltextzugriff (PDF)

First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy

Cancer management and research, 2019-12, Vol.11, p.10463-10476

2019

Volltextzugriff (PDF)

Pomalidomide in combination with dexamethasone results in synergistic anti‐tumour responses in pre‐clinical models of lenalidomide‐resistant multiple myeloma

British journal of haematology, 2016-03, Vol.172 (6), p.889-901

2016

Volltextzugriff (PDF)

Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies

Clinical cancer research, 2019-09, Vol.25 (18), p.5623-5637

2019

Volltextzugriff (PDF)

The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

Clinical cancer research, 2013-10, Vol.19 (20), p.5722-5732

2013

Volltextzugriff (PDF)

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization

Molecular cancer therapeutics, 2015-06, Vol.14 (6), p.1295-1305

2015

Volltextzugriff (PDF)

Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line

The Journal of biological chemistry, 2002-10, Vol.277 (41), p.38884-38894

2002

Volltextzugriff (PDF)

Structure-based optimization of aminothiadiazole inhibitors of AKT

Medicinal chemistry research, 2023-07, Vol.32 (7), p.1426-1435

2023

Volltextzugriff (PDF)

1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4

Bioorganic & medicinal chemistry, 2011-11, Vol.19 (21), p.6356-6374

2011

Volltextzugriff (PDF)

The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-α production with antitumor activity

Cancer research (Chicago, Ill.), 2006-01, Vol.66 (2), p.951-959

2006

Volltextzugriff (PDF)

Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease

Nature medicine, 1995-01, Vol.1 (1), p.53-58

1995

Volltextzugriff (PDF)

AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgkin Lymphoma and CD30 + Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE)

Blood, 2023-11, Vol.142 (Supplement 1), p.4855-4855

2023

Volltextzugriff (PDF)

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes

Annals of hematology, 2022-03, Vol.101 (3), p.557-569

2022

Volltextzugriff (PDF)

Pre-Clinical Efficacy of AB-101, an Allogeneic Cord-Blood Derived Natural Killer (NK) Cell Therapeutic Candidate, in Combination with Anti-CD38 Antibodies in Models of Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.7419-7420

2022

Volltextzugriff (PDF)

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.12742-12743

2022

Volltextzugriff (PDF)

Emerging treatments for asthma

Expert opinion on emerging drugs, 2003-05, Vol.8 (1), p.71-81

2003

Volltextzugriff (PDF)

Abstract 4517: Evaluation of the TOR kinase inhibitor CC214-2 in a mouse model of hormone-refractory prostate cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4517-4517

2014

Volltextzugriff (PDF)

Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor

Journal of medicinal chemistry, 2009-03, Vol.52 (6), p.1522-1524

2009

Volltextzugriff (PDF)

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

Annals of hematology, 2022-01, Vol.101 (3), p.557-569

2022

Volltextzugriff (PDF)

Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-a Inhibitor

Journal of medicinal chemistry, 2009-03, Vol.52 (6), p.1522-1524

2009

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(52)
Dissertationen
(1)

Sprache

Englisch
(53)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro

An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody

Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint

Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G 1 -S Checkpoint

First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy

Pomalidomide in combination with dexamethasone results in synergistic anti‐tumour responses in pre‐clinical models of lenalidomide‐resistant multiple myeloma

Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies

The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization

Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line

Structure-based optimization of aminothiadiazole inhibitors of AKT

1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4

The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-α production with antitumor activity

Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease

AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgkin Lymphoma and CD30 + Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE)

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes

Pre-Clinical Efficacy of AB-101, an Allogeneic Cord-Blood Derived Natural Killer (NK) Cell Therapeutic Candidate, in Combination with Anti-CD38 Antibodies in Models of Multiple Myeloma

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Emerging treatments for asthma

Abstract 4517: Evaluation of the TOR kinase inhibitor CC214-2 in a mouse model of hormone-refractory prostate cancer

Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-a Inhibitor

Suchergebnisse filtern